CLDI (STOCKS)
Calidi Biotherapeutics, Inc.
$0.277000
+0.020500 (+7.99%)
Prev close: $0.256500
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Eric E. Poma
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3.00M
- Employees
- 28
- P/E (TTM)
- -0.04
- P/B (TTM)
- 0.49
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $192.00K |
| Operating Expenses | $20.24M |
| Selling, General, and Administrative Expenses | $10.50M |
| Depreciation and Amortization | $1.65M |
| Research and Development | $9.74M |
| Operating Income/Loss | -$20.24M |
| Income/Loss From Continuing Operations After Tax | -$20.06M |
| Income/Loss From Continuing Operations Before Tax | -$20.05M |
| Income Tax Expense/Benefit | $15.00K |
| Income Tax Expense/Benefit, Current | $15.00K |
| Net Income/Loss | -$20.06M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$157.00K |
| Net Income/Loss Attributable To Parent | -$19.91M |
| Net Income/Loss Available To Common Stockholders, Basic | -$25.58M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $5.67M |
| Preferred Stock Dividends And Other Adjustments | $5.67M |
| Basic Earnings Per Share | -$5.95 |
| Diluted Earnings Per Share | -$5.95 |
| Basic Average Shares | 4,302 |
| Diluted Average Shares | 4,302 |
| Assets | $8.86M |
| Current Assets | $6.26M |
| Noncurrent Assets | $2.60M |
| Fixed Assets | $781.00K |
| Other Non-current Assets | $1.82M |
| Liabilities | $5.10M |
| Current Liabilities | $3.94M |
| Noncurrent Liabilities | $1.16M |
| Long-term Debt | $600.00K |
| Other Non-current Liabilities | $563.00K |
| Equity | $3.76M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.76M |
| Liabilities And Equity | $8.86M |
| Net Cash Flow From Operating Activities | -$21.29M |
| Net Cash Flow From Operating Activities, Continuing | -$21.29M |
| Net Cash Flow From Investing Activities | -$170.00K |
| Net Cash Flow From Investing Activities, Continuing | -$170.00K |
| Net Cash Flow From Financing Activities | $17.46M |
| Net Cash Flow From Financing Activities, Continuing | $17.46M |
| Exchange Gains/Losses | $14.00K |
| Net Cash Flow | -$3.99M |
| Net Cash Flow, Continuing | -$4.00M |
| Comprehensive Income/Loss | -$20.05M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$157.00K |
| Comprehensive Income/Loss Attributable To Parent | -$19.89M |
| Other Comprehensive Income/Loss | $15.00K |